1 / 15

International Conference of Drug Regulatory Authorities (ICDRA):

International Conference of Drug Regulatory Authorities (ICDRA): 13 th ICDRA in during 16-19 September 2008, Berne, Switzerland. Dr Lembit Rägo Quality Assurance and Safety: Medicines (QSM) Essential Medicines and Pharmaceutical Policies (EPM) Health Technology and Pharmaceuticals (HTP)

nelly
Download Presentation

International Conference of Drug Regulatory Authorities (ICDRA):

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. International Conference of Drug Regulatory Authorities (ICDRA): 13th ICDRA in during 16-19 September 2008, Berne, Switzerland Dr Lembit Rägo Quality Assurance and Safety: Medicines (QSM) Essential Medicines and Pharmaceutical Policies (EPM) Health Technology and Pharmaceuticals (HTP) ragol@who.int 1

  2. International Conference of Drug Regulatory Authorities (ICDRA) The International Conference of Drug Regulatory Authorities (ICDRA) provides drug regulatory authorities of WHO Member States with a forum to meet and discuss topics of interest and ways to strengthen collaboration. The ICDRAs have been instrumental in guiding regulatory authorities, WHO and interested stakeholders in determining priorities for action in national and international regulation of medicines, biomedicines (including vaccines and blood products) and traditional medicines.The conferences have been held since 1980 with the aim of promoting exchange of information and collaborative approaches to issues of common concern.

  3. ICDRA: A PARTNERSHIP OF REGULATORY AUTHORITIES • STAKEHOLDERS Regulatory Officials from all WHO regionsICDRA Planning CommitteeMinistry of Health, SwitzerlandDepartment of Foreign AffairsMission Permanente de la Suisse, GenevaSWISSMEDICWHO Headquarters/Director-General, WHOWHO EURO/Regional DirectorWHO technical programmes Regional Advisers from WHO Regions: AFRO AMRO EMRO EURO SEARO WPRO

  4. The 13th ICDRA Pre-conference Berne 14th-15th September 2008 BETTER MEDICINES FOR CHILDREN:THE WAY FORWARD • It is recommended that the World Health Organization: • Convene and collaborate with the global paediatric working group of regulators; • Work with civil society to mobilize and empower consumers, parents, patients' groups and health professionals to advocate for better medicines for children; • Address high priority needs with achievable results including: • Zinc for diarrhoea, pneumonia treatment, neonatal sepsis, HIV, TB, malaria treatments, analgesia, drugs for chronic disease in children; • Take steps to identify the priorities and treatment guidelines needed for neonates; • Establish mechanisms to support drug development of new essential medicines for children.

  5. 13th ICDRA PLENARY SESSIONS • Plenary 1: Opening Ceremony • Welcome address. • Christine Beerli, Chairwoman of the Institute Council, Swissmedic, Switzerland • Opening speech. • Carissa Etienne, Assistant Director-General, World Health Organization

  6. Plenary 2: Update on 12th ICDRA • Reflections on 12th ICDRA, Chung Keel Lee, Republic of Korea • WHO Progress Report, Hans Hogerzeil, WHO • WHO Progress Report from countries: regional perspectives. • WHO Regional Advisers on Pharmaceuticals: • AFRO progress report, J. M. Trapsida • AMRO/PAHO progress report, J. Fitzgerald • EMRO Progress Report, Z. Mirza • EURO, Progress Report, Kees de Joncheere • SEARO, Progress Report, K. Weerasuriya • WPRO, Progress Report, B. Santoso

  7. Plenary 3: Building mutual trust as a key to access (I) • WHO should: • Promote, in a targeted and prioritized way, adoption and implementation of the WHO Model Registration Package as minimum information requirements for product registration. • Produce a guidance and draft regulation for managing confidentiality issues among regulatory authorities. • Undertake joint assessments of selected applications, using the Model Registration Package. • Foster the development of regional, collaborative post-market surveillance and pharmacovigilance systems to monitor the quality, safety and efficacy of health products.

  8. Plenary 3: Building mutual trust as a key to access (II) • WHO should: • Explore the potential development of an inter-agency e-governance working group to harmonize electronic requirements to assist in the development of regulatory management systems and the sharing of information in accordance with established WHO international regulatory norms and standards. • In partnership with well-resourced regulatory authorities: • establish formal mechanisms for the exchange and use of regulatory information among all authorities to strengthen capacity and to maximize efficiencies, and • facilitate cooperation between small and medium well-resourced regulatory authorities to develop systems for the abbreviated assessment, approval and monitoring of health products.

  9. Plenary 4: Regulatory systems in a changing environment • Recommendations • Member states should • Facilitate and speed up global regulatory cooperation. • Support and stimulate their regulatory authorities to work with regional and global partners. • WHO should: • Continue to support and create new activities that stimulate trust building and cooperation among regulatory agencies.

  10. Plenary 5. Crisis management: safeguarding health • Recommendations • Member States should • Have in place a standard operating procedure for communication in times of crisis. Main initial communication difficulties which are linked to uncertainty of toxicity implications could be avoided by use of such SOPs. … • WHO and Member States should • Work further to integrate and coordinate information and other requirements in the International Health Regulations (IHR) (2005) with functions and activities of medicines regulatory authorities and related networks. Such integration could include establishing links between medicines regulatory authorities and their respective national IHR focal points, including potential access to the WHO IHR Event Information Site.

  11. Plenary 6: Current topics • Good Governance for Medicines • Variations • Challenges in regulating radiopharmaceuticals • Involving consumers in medicines surveillance reporting. • WHO Stability Testing Guideline • Revision of WHO stability testing guidelines. • WHO Certification Scheme • Adverse reactions related to change of formulation: thyroxine case.

  12. WORKSHOPS (I) • Workshop A: Regulatory aspects of paediatric medicines • Workshop B: Development of regulation for herbal medicines • Workshop C: Safety and pandemic preparedness • Workshop D: Regulatory approaches to proving interchangeability • Workshop E: Strategies to fight counterfeit medicines • Workshop F: Emerging regulatory issues concerning biosimilars and biologicals

  13. WORKSHOPS (II) • Workshop G: Emerging diseases: regulating blood products • Workshop H: Regulators contribution to access • Workshop I: Update on harmonization initiatives • Workshop J: Role of regulators in clinical trial approval • Workshop K. Building regulatory capacity: best practices for the future • Workshop L. GMP inspections: impact of information sharing and risk management

  14. OUTPUTS • Report • Recommendations • Website • Communications, • Professional and personal • contacts

  15. Next 14th ICDRA - where? • Singapore 2010

More Related